

Title (en)  
COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN

Publication  
**EP 0573581 A4 19940629 (EN)**

Application  
**EP 92907852 A 19920226**

Priority  
• US 66155491 A 19910226  
• US 74763591 A 19910820

Abstract (en)  
[origin: WO9214453A1] Sympathetically maintained pain is treated topically by administering to the site where sympathetically maintained pain is present an alpha -1-adrenergic antagonist, alpha -2-adrenergic agonist, or other drug that depletes or blocks synthesis of sympathetic norepinephrine, known collectively as sympatholytic agents. Chemical formulas for several sympatholytic agents are given.

IPC 1-7  
**A61K 31/04**

IPC 8 full level  
**A61K 31/135** (2006.01); **A61K 31/155** (2006.01); **A61K 31/165** (2006.01); **A61K 31/18** (2006.01); **A61K 31/335** (2006.01); **A61K 31/395** (2006.01); **A61K 31/40** (2006.01); **A61K 31/415** (2006.01); **A61K 31/425** (2006.01); **A61K 31/44** (2006.01); **A61K 31/4402** (2006.01); **A61K 31/4412** (2006.01); **A61K 31/4418** (2006.01); **A61K 31/445** (2006.01); **A61K 31/47** (2006.01); **A61K 31/475** (2006.01); **A61K 31/48** (2006.01); **A61K 31/495** (2006.01); **A61K 31/505** (2006.01); **A61K 31/54** (2006.01); **A61K 31/55** (2006.01); **A61P 25/02** (2006.01); **A61P 25/04** (2006.01); **C07D 207/08** (2006.01); **C07D 207/16** (2006.01); **C07D 213/54** (2006.01); **C07D 213/79** (2006.01); **C07D 213/83** (2006.01); **C07D 239/78** (2006.01)

CPC (source: EP US)  
**A61K 31/135** (2013.01 - EP); **A61K 31/155** (2013.01 - EP); **A61K 31/165** (2013.01 - EP); **A61K 31/18** (2013.01 - EP); **A61K 31/335** (2013.01 - EP); **A61K 31/395** (2013.01 - EP US); **A61K 31/40** (2013.01 - EP); **A61K 31/415** (2013.01 - EP); **A61K 31/425** (2013.01 - EP); **A61K 31/44** (2013.01 - EP); **A61K 31/445** (2013.01 - EP); **A61K 31/47** (2013.01 - EP); **A61K 31/475** (2013.01 - EP); **A61K 31/48** (2013.01 - EP); **A61K 31/495** (2013.01 - EP); **A61K 31/505** (2013.01 - EP); **A61K 31/54** (2013.01 - EP); **A61K 31/55** (2013.01 - EP); **A61P 25/02** (2017.12 - EP); **A61P 25/04** (2017.12 - EP)

Citation (search report)  
• [X] A.L. CURTIS ET AL.: "Evidence for alpha adrenoceptor modulation of the nociceptive jaw-opening reflex in rats and rabbits.", J. PHARMACOL. EXP. THER., vol. 238, no. 2, 1986, pages 576 - 579  
• [X] J. SAGEN ET AL.: "Evidence for pain modulation by pre-and postsynaptic noradrenergic receptors in the medulla oblongata.", BRAIN RES., vol. 331, no. 2, 1985, pages 285 - 293  
• [X] M. ISHIZUKI: "Clinical application of guanethidine ointment to the treatment of painful states and allodynia.", CLIN. J. PAIN, vol. 4, no. 4, 1988, pages 261  
• See references of WO 9214453A1

Designated contracting state (EPC)  
AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

DOCDB simple family (publication)  
**WO 9214453 A1 19920903**; CA 2104873 A1 19920903; CA 2104873 C 20000523; EP 0573581 A1 19931215; EP 0573581 A4 19940629; JP H06507392 A 19940825

DOCDB simple family (application)  
**US 9201543 W 19920226**; CA 2104873 A 19920226; EP 92907852 A 19920226; JP 50739292 A 19920226